Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2021)

Alnylam Pharmaceuticals has reported Non-Current Debt for 6 years, with the latest figure at $675.7 million in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Debt rose 253.25% year-over-year to $675.7 million; the trailing twelve-month figure through Dec 2021 stood at $675.7 million (up 253.25% YoY), and the FY2021 full-year result was $675.7 million, up 253.25% from the prior year.
• Non-Current Debt for Q4 2021 stood at $675.7 million, up from $191.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $675.7 million in Q4 2021, with the low at $30.0 million in Q4 2017.
• Historically, Non-Current Debt has averaged $127.2 million across 5 years, with a median of $30.0 million in 2017.
• Annual changes were most pronounced in 2017 — Non-Current Debt slumped 80.0% — and 2021, when it surged 253.25%.
• Alnylam Pharmaceuticals' Non-Current Debt stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then jumped by 537.59% to $191.3 million in 2020, then surged by 253.25% to $675.7 million in 2021.
• The last three Non-Current Debt figures came in at $675.7 million (Q4 2021), $191.3 million (Q4 2020), and $30.0 million (Q2 2019), per Business Quant data.